ENDRA Life Sciences Receives Approval to Initiate Human Studies of its TAEUS(TM) Device Targeting Non-Alcoholic Fatty Liver Disease

Stock Information for ENDRA Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ENDRA Life Sciences Inc.

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
ENDRA Life Sciences Installs First TAEUS System in the UK
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.